• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用微流控装置或烧杯制备的聚乳酸-羟基乙酸共聚物(PLGA)微粒的释放机制

Release mechanisms of PLGA microparticles prepared using a microfluidics device or a beaker.

作者信息

Lefol L A, Sodano A, Bawuah P, Zeitler J A, Verin J, Danede F, Willart J F, Siepmann J, Siepmann F

机构信息

Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.

Univ. Cambridge, Department of Chemical Engineering and Biotechnology, Cambridge CB3 0AS, UK.

出版信息

Int J Pharm X. 2025 Jul 23;10:100366. doi: 10.1016/j.ijpx.2025.100366. eCollection 2025 Dec.

DOI:10.1016/j.ijpx.2025.100366
PMID:40791746
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12337791/
Abstract

The aim of this study was to better understand the release mechanisms of poly(lactic--glycolic acid) (PLGA) microparticles prepared via emulsification - solvent extraction/evaporation using a "classical beaker" vs. a "microfluidics device". Ibuprofen-loaded microparticles were studied by optical microscopy, SEM, X-ray powder diffraction, X-ray μCT and drug release measurements from microparticles in well agitated phosphate buffer pH 7.4 or agarose gel (mimicking living tissue). The use of a microfluidics device facilitated the preparation of microparticles with a less broad size distribution. However, in addition to the microparticle size, the inner system structure was found to be also of utmost importance for the resulting drug release kinetics in this case. Interestingly, even microparticles with exhibited a . This was true, irrespective of the type of preparation method and experimental release set-up, and could be explained as follows: The investigated microparticles were characterized by a continuous inner pore network and an initially smooth & non-porous surface. Drug release set on as soon as: (i) the pore network got direct access to the release medium (e.g., due to a "weak point" in the PLGA surface layer), or (ii) substantial system swelling started (after a lag-time of several days). Importantly, microparticle had its own, specific structure, which determined "" to release the drug. Furthermore, the experimental conditions were found to be of key importance: The presence of a surrounding agarose gel protected the microparticles from damage caused by convective fluid flow, and hindered microparticle swelling, thus, slowing down drug release.

摘要

本研究的目的是更深入地了解通过乳化 - 溶剂萃取/蒸发法,使用“经典烧杯”与“微流控装置”制备聚乳酸 - 乙醇酸共聚物(PLGA)微粒的释放机制。通过光学显微镜、扫描电子显微镜(SEM)、X射线粉末衍射、X射线显微计算机断层扫描(X射线μCT)以及在pH 7.4的充分搅拌的磷酸盐缓冲液或琼脂糖凝胶(模拟活体组织)中对微粒进行药物释放测量,对载布洛芬微粒进行了研究。使用微流控装置有助于制备尺寸分布较窄的微粒。然而,在这种情况下,除了微粒尺寸外,内部系统结构对于最终的药物释放动力学也至关重要。有趣的是,即使是具有[此处原文缺失相关描述]的微粒也表现出[此处原文缺失相关描述]。无论制备方法的类型和实验释放设置如何,都是如此,其原因如下:所研究的微粒具有连续的内部孔隙网络和初始光滑且无孔的表面。药物释放一旦开始:(i)孔隙网络直接与释放介质接触(例如,由于PLGA表面层中的“弱点”),或(ii)在经过几天的滞后时间后开始大量系统溶胀。重要的是,每个微粒都有其自身特定的结构,该结构决定了[此处原文缺失相关描述]以释放药物。此外,发现实验条件至关重要:周围琼脂糖凝胶的存在保护微粒免受对流流体流动造成的损害,并阻碍微粒溶胀,从而减缓药物释放。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/e1f04b2cd1cf/gr10a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/8e14ca272bcf/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/2f77606e8f20/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/7458b13ad1ef/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/19c464322a6f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/96eec2935af8/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/f2c0a0fc0f85/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/119fe04cc554/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/6e5b6bddc952/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/53c06562aff6/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/517098a5d86c/gr9a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/e1f04b2cd1cf/gr10a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/8e14ca272bcf/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/2f77606e8f20/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/7458b13ad1ef/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/19c464322a6f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/96eec2935af8/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/f2c0a0fc0f85/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/119fe04cc554/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/6e5b6bddc952/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/53c06562aff6/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/517098a5d86c/gr9a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b51f/12337791/e1f04b2cd1cf/gr10a.jpg

相似文献

1
Release mechanisms of PLGA microparticles prepared using a microfluidics device or a beaker.使用微流控装置或烧杯制备的聚乳酸-羟基乙酸共聚物(PLGA)微粒的释放机制
Int J Pharm X. 2025 Jul 23;10:100366. doi: 10.1016/j.ijpx.2025.100366. eCollection 2025 Dec.
2
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
3
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
4
Microfluidic Regulation of Core-Shell PLGA Microspheres for Sustained Release of Leuprolide Acetate.用于醋酸亮丙瑞林持续释放的核壳聚乳酸-羟基乙酸共聚物微球的微流控调控
Langmuir. 2025 Jul 15;41(27):17893-17901. doi: 10.1021/acs.langmuir.5c01667. Epub 2025 Jul 2.
5
Drug release from PLGA microparticles can be slowed down by a surrounding hydrogel.周围的水凝胶可以减缓药物从聚乳酸-羟基乙酸共聚物(PLGA)微粒中的释放。
Int J Pharm X. 2023 Nov 28;6:100220. doi: 10.1016/j.ijpx.2023.100220. eCollection 2023 Dec 15.
6
Poly(Lactic-Co-Glycolic Acid) Microparticles for the Delivery of Model Drug Compounds for Applications in Vascular Tissue Engineering.用于递送模型药物化合物的聚(乳酸-乙醇酸)微粒在血管组织工程中的应用
Cells Tissues Organs. 2024;213(6):475-485. doi: 10.1159/000539971. Epub 2024 Jun 22.
7
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
8
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
Inhaled mannitol for cystic fibrosis.吸入用甘露醇治疗囊性纤维化。
Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3.

本文引用的文献

1
PLGA-based long-acting injectable (LAI) formulations.基于聚乳酸-羟基乙酸共聚物的长效注射剂(LAI)制剂。
J Control Release. 2025 Jun 10;382:113758. doi: 10.1016/j.jconrel.2025.113758. Epub 2025 Apr 21.
2
Drug release from PLGA microparticles can be slowed down by a surrounding hydrogel.周围的水凝胶可以减缓药物从聚乳酸-羟基乙酸共聚物(PLGA)微粒中的释放。
Int J Pharm X. 2023 Nov 28;6:100220. doi: 10.1016/j.ijpx.2023.100220. eCollection 2023 Dec 15.
3
A comparative study of PLGA microparticle properties loaded with micronized, nanosized or dissolved drug.
载药微米化、纳米化或溶解的 PLGA 微球性质的比较研究。
Int J Pharm. 2022 Nov 25;628:122313. doi: 10.1016/j.ijpharm.2022.122313. Epub 2022 Oct 19.
4
Implications of particle size on the respective solid-state properties of naltrexone in PLGA microparticles.粒径对 PLGA 微球中纳曲酮各自固态性能的影响。
Int J Pharm. 2022 Oct 15;626:122170. doi: 10.1016/j.ijpharm.2022.122170. Epub 2022 Sep 5.
5
Transitioning from a lab-scale PLGA microparticle formulation to pilot-scale manufacturing.从实验室规模的 PLGA 微球制剂向中试规模生产的转变。
J Control Release. 2022 Aug;348:841-848. doi: 10.1016/j.jconrel.2022.06.036. Epub 2022 Jun 28.
6
Microfluidic Systems For Manufacturing of Microparticle-Based Drug-Delivery Systems: Design, Construction, and Operation.微流控系统在基于微粒的药物输送系统制造中的应用:设计、构建和操作。
ACS Biomater Sci Eng. 2022 Jul 11;8(7):2864-2877. doi: 10.1021/acsbiomaterials.2c00066. Epub 2022 Jun 8.
7
An in vitro gel-based system for characterizing and predicting the long-term performance of PLGA in situ forming implants.一种基于体外凝胶的系统,用于表征和预测 PLGA 原位形成植入物的长期性能。
Int J Pharm. 2021 Nov 20;609:121183. doi: 10.1016/j.ijpharm.2021.121183. Epub 2021 Oct 12.
8
Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Monolithic dispersions studied at lower temperatures.PLGA 微球(高达)3 个释放阶段的机理解释:在较低温度下研究的整体分散体。
Int J Pharm. 2021 Mar 1;596:120220. doi: 10.1016/j.ijpharm.2021.120220. Epub 2021 Jan 22.
9
Phenomenology of the Initial Burst Release of Drugs from PLGA Microparticles.药物从聚乳酸-羟基乙酸共聚物(PLGA)微粒中的初始突释现象学
ACS Biomater Sci Eng. 2020 Nov 9;6(11):6053-6062. doi: 10.1021/acsbiomaterials.0c01228. Epub 2020 Oct 9.
10
Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles.聚(丙交酯-乙交酯)微球的配方组成、制造工艺和特性描述。
J Control Release. 2021 Jan 10;329:1150-1161. doi: 10.1016/j.jconrel.2020.10.044. Epub 2020 Oct 24.